Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zenas BioPharma (ZBIO) Enterprise Value (2023 - 2025)

Zenas BioPharma has reported Enterprise Value over the past 3 years, most recently at -$343.2 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$343.2 million for Q4 2025, down 7.3% from a year ago — trailing twelve months through Dec 2025 was -$343.2 million (down 7.3% YoY), and the annual figure for FY2025 was -$343.2 million, down 7.3%.
  • Enterprise Value for Q4 2025 was -$343.2 million at Zenas BioPharma, down from -$290.9 million in the prior quarter.
  • Over the last five years, Enterprise Value for ZBIO hit a ceiling of -$37.2 million in Q1 2024 and a floor of -$430.0 million in Q1 2025.
  • Median Enterprise Value over the past 3 years was -$282.1 million (2025), compared with a mean of -$236.8 million.
  • Peak annual rise in Enterprise Value hit 19.23% in 2025, while the deepest fall reached 1054.74% in 2025.
  • Zenas BioPharma's Enterprise Value stood at -$56.9 million in 2023, then tumbled by 462.52% to -$319.8 million in 2024, then dropped by 7.3% to -$343.2 million in 2025.
  • The last three reported values for Enterprise Value were -$343.2 million (Q4 2025), -$290.9 million (Q3 2025), and -$273.3 million (Q2 2025) per Business Quant data.